Shots:
- Eli Lilly has entered into a definitive agreement to acquire Ventyx, strengthening Lilly’s capabilities in inflammatory-mediated diseases
- As per the deal, Eli Lilly will acquire Ventyx for $14/share in an all-cash transaction, representing an aggregate equity value of ~$1.2B; closing is expected in H1’26
- Ventyx is advancing a pipeline of oral small-molecule therapies, incl. NLRP3 inhibitors, aimed at treating inflammation across high-unmet-need cardiometabolic, neurodegenerative & inflammatory diseases
Ref: Eli Lilly | Image: Ventyx | Press Release
Related News: Nimbus Therapeutics and Eli Lilly Enter ~$1.3B Deal to Develop Oral Metabolic Therapies
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
T
